UBS Group
ETRM

UBS Group’s EnteroMedics Inc. ETRM Stock Holding History

UBS Group’s Portfolio ETRM Stock Details ETRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,940
Closed -$3K – 8534
2017
Q3 		$3K Sell
1,940
-3,595
-65% -$10.6K ﹤0.01% 7451
2017
Q2 		$28K Sell
5,535
-3,678
-40% -$18.3K ﹤0.01% 6070
2017
Q1 		$53K Buy
9,213
+8,110
+735% +$60K ﹤0.01% 5495
2016
Q4 		$2K Sell
1,103
-699
-39% -$3.67K ﹤0.01% 7589
2016
Q3 		$17K Buy
1,802
+1,686
+1,453% +$22.9K ﹤0.01% 6461
2016
Q2 		$2K Sell
116
-7
-6% -$321 ﹤0.01% 7518
2016
Q1 		$8K Buy
123
+98
+392% +$7.92K ﹤0.01% 6829
2015
Q4 		$3K Sell
25
-40
-62% -$8.29K ﹤0.01% 7976
2015
Q3 		$18K Buy
+65
New +$20.8K ﹤0.01% 6839
2015
Q2 		– Sell
-15
Closed -$14K – 9388
2015
Q1 		$14K Sell
15
-1
-6% -$1.21K ﹤0.01% 7409
2014
Q4 		$24K Buy
+16
New +$21.6K ﹤0.01% 7431

Other funds holding ETRM

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

UBS Group's ETRM Position: Q4 2017 in Review

UBS Group sold out of EnteroMedics Inc. (ETRM) in Q4 2017, closing a stake of 1,940 shares — an estimated $3K sold.

UBS Group first reported a position in ETRM in Q4 2014 and held it in 11 quarters. The position peaked at $53K in Q1 2017. 1 fund tracked by Wall St. Rank holds ETRM as of Q4 2017.

  • UBS Group reported no remaining EnteroMedics Inc. position as of Q4 2017 after selling out during the quarter.
  • UBS Group sold 1,940 EnteroMedics Inc. shares in Q4 2017, an estimated $3K.
  • UBS Group first reported a position in EnteroMedics Inc. in Q4 2014 and held it in 11 quarters.
  • UBS Group's EnteroMedics Inc. position peaked at $53K in Q1 2017.
  • 1 fund tracked by Wall St. Rank held EnteroMedics Inc. as of Q4 2017.

Based on UBS Group's 13F filing for Q4 2017, filed 14 Feb 2018.